Who Are We
NeuroCytonix. Inc. is a biomedical technology company focused on developing innovative revolutionary treatments for neurodegenerative diseases such as cerebral palsy, stroke, and traumatic brain injuries. Our company was founded in 2017 by Dr. J. Roberto Trujillo to find cures for incurable neurological diseases.
We have our corporate headquarters in Rockville, Maryland, USA near the US National Institutes of Health (NIH). In 2018, we established our clinical center in Monterrey, Mexico, in compliance with the FDA rules of “Good Clinical Practice” (GCP).
Our mission is to help people around the world with treatments for a range of diseases of the brain and nervous system.
Our team is committed to establishing treatments for incurable neurological diseases through our innovative biomedical technology.
How does our technology help?
Neurodegenerative diseases are a condition that affects brain cells known as neurons. Communication between the brain and the rest of the body is facilitated by neurons. When neurons are damaged, there is a loss of brain activity that results in issues with movement and cognitive function. Neurodegenerative damage to distinct parts of the brain creates different symptoms.
Our technology utilizes the combination of magnetic fields and radiofrequency waves to stimulate brain regeneration and restore the broken neural network. The protocols developed helps to improve the quality of life of patients while the brain starts to heal.
Clinical Trials
Clinical trials help us evaluate the safety and efficacy of protocols developed for different neurological diseases. Our clinical trials are only conducted after careful analysis of the patient's health and medical history to ensure that they are eligible for the protocol. We ensure that every clinical trial is planned, conducted, and reviewed in compliance with the highest scientific, ethical, and clinical standards. In addition, we follow Good Clinical Practice (GCP) guidelines that are required by our regulators to protect the patient's rights, integrity, and confidentiality.
Mexican regulatory authority COFEPRIS has acknowledged the results of our double-blind, randomized, placebo-controlled clinical trial which provides safety and efficacy data of our biomedical technology for children with cerebral palsy. Studies in the development of protocols for other neurological diseases such as stroke, traumatic brain injury (TBI), as well as neurological complications associated with COVID-19 are in progress.
To know more about our clinical trial, please check a full description on ClinicalTrials.gov